Inhalative Analgosedierung auf der Intensivstation: Gefahr einer malignen Hyperthermie

Translated title of the contribution: Inhalational analgosedation in the intensive care unit: Risk of malignant hyperthermia

W. Klingler, E. Pfenninger

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: According to the 2010 S3 Guidelines, analgosedation is an option for ventilated patients in intensive care units (ICU). Therefore, adverse effects of volatile anesthetics can occur in areas outside of surgical medical fields. Objective: The aim is to inform ICU physicians about the clinical and legal challenges of a life-threatening pharmacogenetic reaction to inhalational anesthetics, malignant hyperthermia (MH). Discussion: Consequences of an MH crisis for doctors, patients, and relatives regarding patient rights legislation, as well as insurance and employment issues with respect to the German Genetic Diagnostics Act are discussed.

Translated title of the contributionInhalational analgosedation in the intensive care unit: Risk of malignant hyperthermia
Original languageGerman
Pages (from-to)101-106
Number of pages6
JournalMedizinische Klinik - Intensivmedizin und Notfallmedizin
Volume115
Issue number2
DOIs
StatePublished - 1 Mar 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Inhalational analgosedation in the intensive care unit: Risk of malignant hyperthermia'. Together they form a unique fingerprint.

Cite this